PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-6.63%
Negative revenue growth while MRVL stands at 0.06%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-7.29%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-5.86%
Negative EBIT growth while MRVL is at 5.13%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-6.38%
Negative operating income growth while MRVL is at 5.13%. Joel Greenblatt would press for urgent turnaround measures.
-0.12%
Negative net income growth while MRVL stands at 3.37%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.26%
Share reduction while MRVL is at 1.15%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-1.02%
Reduced diluted shares while MRVL is at 1.85%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
13.02%
Dividend growth above 1.5x MRVL's 0.12%. David Dodd would verify if the firm's cash flow is robust enough for these payouts.
-8.03%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-10.39%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
70.78%
10Y revenue/share CAGR under 50% of MRVL's 287.20%. Michael Burry would suspect a lasting competitive disadvantage.
29.09%
5Y revenue/share CAGR under 50% of MRVL's 122.25%. Michael Burry would suspect a significant competitive gap or product weakness.
3.75%
3Y revenue/share CAGR under 50% of MRVL's 34.81%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
60.55%
10Y OCF/share CAGR under 50% of MRVL's 151.60%. Michael Burry would worry about a persistent underperformance in cash creation.
50.79%
5Y OCF/share CAGR above 1.5x MRVL's 12.63%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
42.19%
Positive 3Y OCF/share CAGR while MRVL is negative. John Neff might see a big short-term edge in operational efficiency.
177.33%
Below 50% of MRVL's 445.16%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
49.47%
Below 50% of MRVL's 300.65%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
200.49%
Positive short-term CAGR while MRVL is negative. John Neff would see a clear advantage in near-term profit trajectory.
31.01%
Below 50% of MRVL's 115.78%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
26.82%
5Y equity/share CAGR at 50-75% of MRVL's 49.39%. Martin Whitman would question a shortfall in capital accumulation vs. the competitor.
2.97%
Below 50% of MRVL's 10.33%. Michael Burry suspects a serious short-term disadvantage in building book value.
1232.73%
Dividend/share CAGR of 1232.73% while MRVL is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
183.53%
Dividend/share CAGR of 183.53% while MRVL is zero. Bruce Berkowitz sees a minor advantage in stepping up distributions, even modestly.
100.21%
3Y dividend/share CAGR of 100.21% while MRVL is zero. Bruce Berkowitz sees a minor positive difference that could attract dividend-focused investors.
-15.64%
Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.
1.88%
We show growth while MRVL is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
-0.99%
Negative asset growth while MRVL invests at 1.93%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
0.49%
Under 50% of MRVL's 3.79%. Michael Burry raises concerns about the firm’s ability to build intrinsic value relative to its rival.
-0.06%
We’re deleveraging while MRVL stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-6.33%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-7.34%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.